

Frequently Asked Questions

Who orders Decipher Bladder?

Decipher Bladder is ordered by your doctor or healthcare provider. It uses tissue that has already been collected, so no additional procedure is needed.

What is tumor genomic testing?

Tumor genomic testing looks at the activity of genes within the cancer tissue, which can provide insight into how the cancer may behave.

Does Decipher Bladder test my DNA?

No. Decipher Bladder measures gene activity by analyzing the tumor's RNA. It does not test your inherited DNA.

What information is used to determine my Decipher Bladder result?

The test result is based on the activity of 219 genes in your bladder tumor tissue and is separate from clinical information such as tumor stage or pathology.

What is a TURBT?

A Transurethral Resection of Bladder Tumor (TURBT) is a minimally invasive procedure used to diagnose and treat bladder cancer. A small camera is inserted into the bladder, and a wire loop is used to remove the tumor.

What is clinical staging?

Clinical staging estimates how far the cancer has grown or spread based on the tumor removed during your TURBT and imaging tests.

Contact Us!



client.service-urology@veracyte.com



1.888.792.1601



[https://www.veracyte.com/
tests/decipher-bladder/
patients/](https://www.veracyte.com/tests/decipher-bladder/patients/)

OR

Scan QR Code



Guidelines & Coverage

- Decipher Bladder is covered by **Medicare** for patients with clinical stage T1-T4a bladder cancer.
- Financial assistance and flexible payment options are available through the **Veracyte Access** program for commercially insured and self-pay patients.

Scan to find Decipher Bladder patient resources:



Household Size	Cost to Patient		
	\$0	\$100	\$295
1	\$46,950	\$54,775	\$62,600
2	\$63,450	\$74,025	\$84,600
3	\$79,950	\$93,275	\$106,600
4	\$96,450	\$112,525	\$128,600
5	\$112,950	\$131,775	\$150,600
2026 maximum household income*			

*Veracyte Access eligibility is based on total annual household income, insurance status, and household size. Some eligibility restrictions apply. Veracyte offers certain Decipher tests at a reduced cost to eligible applicants except where otherwise restricted. Residents of the United States, District of Columbia and Puerto Rico are eligible to apply. Veracyte Access does not constitute health insurance. You must meet certain income requirements set forth above. We may request documentation to verify your income, including recently filed tax returns and other supporting documentation. By requesting assistance, you certify, to the best of your knowledge, that you are eligible for assistance and that you have insufficient financial resources to pay for the ordered test. We may discontinue or change this program at any time for any reason without notice.

© 2026 Veracyte, Inc. All rights reserved. Decipher, Veracyte, and the Veracyte logo are registered trademarks of Veracyte. Decipher Bladder is available in the United States as part of Veracyte's CLIA-Validated laboratory developed test (LDT) service, and FDA clearance is not required.

MRKT-FRM-10051



Decipher Bladder


Personalized insights
to help guide bladder
cancer care



Talk to your doctor about
whether Decipher Bladder
may be right for you.

Decipher Bladder: An overview

- A genomic test that provides a molecular subtype of your tumor to help better understand its biology and support treatment decisions.
- Provides information beyond standard pathology and staging.
- Intended for patients with clinical stage T1 through T4a bladder cancer.
- Performed on tissue already collected during your TURBT. No additional procedure is needed.



What is molecular subtyping?

Molecular subtyping groups bladder cancers based on their underlying biology.

Decipher Bladder is a molecular subtyping tool that analyzes the activity of 219 genes from your tumor.

Why did my doctor order Decipher Bladder?

Clinical staging shows how far the cancer has spread, but it does not always show how aggressive it may be.

Decipher Bladder adds information beyond standard staging and pathology and may help your doctor understand:

Whether the cancer may be more aggressive than expected

The chance that the cancer may progress

Which treatments may be most appropriate for you

Understanding your results

Your Decipher Bladder results group your tumor into one of two main molecular subtype categories.

Luminal Subtypes

Often associated with:

- Less aggressive disease
- Lower risk of progression
- Distinct responses to certain treatments

Luminal

Non-Luminal Subtypes

Often associated with:

- More aggressive disease
- Higher risk of progression
- Greater likelihood of benefit from treatments such as chemotherapy or immunotherapy in some patients

Infiltrated

Basal

Basal Claudin-Low

Neuroendocrine-Like

Decipher Bladder does not determine treatment on its own. Your doctor will review the results along with other clinical information to help guide treatment decisions.